Abstract 5620
Background
Radiotherapy involves many short visits to the hospital during several weeks. Side effects may occur after a few weeks of daily treatment. This includes problems with urination, urgency, bowel problems, and often a disturbed sleep. A research team at Karolinska University Hospital in Sweden attempted to understand how the patients with prostate cancer experience the radiation therapy, as well as how the therapy affects their daily life.
Methods
Ten prostate cancer patients from two different hospitals in Stockholm were asked to keep diaries, and subsequently interviewed about their experiences of radiation treatment. Data were analyzed with Framework content analysis.
Results
Three themes emerged after analysis: Changed life situation because of radiation treatment and its side effects and cancer diagnosis; Guidance by oncology nurses, oncologist and close relatives and own reflection the patients got; New Perspectives after weeks of treatment. With New perspectives they could find routines for their daily life and cope with side effects and cancer diagnosis.
Conclusions
Despite the stressful situation caused by side effects affecting daily life, patients with prostate cancer receiving radiation therapy generally describe their treatment period as positive. In the beginning, the treatment period is perceived as a journey with a sense of uncertainty, which gradually turns into a sense of increased certainty and stability as the treatment proceeds. The patients describe their partner as the most important support and guide through the journey of radiation therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4097 - Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option
Presenter: Stephen V Liu
Session: Poster Display session 3
Resources:
Abstract
1129 - Aspirin and Ticagrelor for the prevention of tumour cell induced platelet aggregation
Presenter: Meera Chauhan
Session: Poster Display session 3
Resources:
Abstract
4514 - Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Presenter: Michele Maio
Session: Poster Display session 3
Resources:
Abstract
5169 - In vitro functional interrogation of viable Circulating Tumor Associated Cells (C-TACs) for evaluating Platin resistance.
Presenter: Stefan Schuster
Session: Poster Display session 3
Resources:
Abstract
5827 - Targeting ARG2 as a novel therapeutic approach for cancer
Presenter: Marcin Grzybowski
Session: Poster Display session 3
Resources:
Abstract
3129 - MPS1 and PLK1 as new therapy targets in TP53 mutated solid tumors
Presenter: Balazs Gyorffy
Session: Poster Display session 3
Resources:
Abstract
2129 - The Tumor Static Exposure (TSE) concept & utility: application to combination treatment of radiation and radiosensitizing agent in tumor xenograft experiments
Presenter: Samer El Bawab
Session: Poster Display session 3
Resources:
Abstract
1814 - General Methodology to Optimize Tumor Treating Fields Delivery Utilizing Numerical Simulations
Presenter: Noa Urman
Session: Poster Display session 3
Resources:
Abstract
3010 - The Australian Exceptional Responders Program: a National collaboration
Presenter: Megan Barnet
Session: Poster Display session 3
Resources:
Abstract
4489 - A Window of Opportunity Trial of Atorvastatin Targeting p53 Mutant Malignancies
Presenter: Joaquina Baranda
Session: Poster Display session 3
Resources:
Abstract